Literature DB >> 16941092

Proton MRI appearance of cystic fibrosis: comparison to CT.

Michael Puderbach1, Monika Eichinger, Julie Gahr, Sebastian Ley, Siegfried Tuengerthal, Astrid Schmähl, Christian Fink, Christian Plathow, Matthias Wiebel, Frank-Michael Müller, Hans-Ulrich Kauczor.   

Abstract

Cystic fibrosis (CF) is the most frequent inherited disorder leading to premature death in the Caucasian population. As life expectancy is limited by pulmonary complications, repeated imaging [chest X-ray, multislice high-resolution computed tomography (MS-HRCT)] is required in the follow-up. Magnetic resonance imaging (MRI) of the lung parenchyma is a promising new diagnostic tool. Its value for imaging lung changes caused by CF compared with CT is demonstrated. MRI performs well when compared with CT, which serves as the gold standard. Its lack in spatial resolution is obvious, but advantages in contrast and functional assessment compensate for this limitation. Thus, MRI is a reasonable alternative for imaging the CF lung and should be introduced as a radiation-free modality for follow-up studies in CF patients. For further evaluation of the impact of MRI, systematic studies comparing MRI and conventional imaging modalities are necessary. Furthermore, the value of the additional functional MRI (fMRI) information has to be studied, and a scoring system for the morphological and functional aspect of MRI has to be established.

Entities:  

Mesh:

Year:  2006        PMID: 16941092     DOI: 10.1007/s00330-006-0373-4

Source DB:  PubMed          Journal:  Eur Radiol        ISSN: 0938-7994            Impact factor:   5.315


  26 in total

1.  Resolution enhancement in lung 1H imaging using parallel imaging methods.

Authors:  R M Heidemann; M A Griswold; B Kiefer; M Nittka; J Wang; V Jellus; P M Jakob
Journal:  Magn Reson Med       Date:  2003-02       Impact factor: 4.668

2.  Regional lung perfusion: assessment with partially parallel three-dimensional MR imaging.

Authors:  Christian Fink; Michael Puderbach; Michael Bock; Klaus-Peter Lodemann; Ivan Zuna; Astrid Schmähl; Stefan Delorme; Hans-Ulrich Kauczor
Journal:  Radiology       Date:  2004-04       Impact factor: 11.105

3.  Evaluation of chest motion and volumetry during the breathing cycle by dynamic MRI in healthy subjects: comparison with pulmonary function tests.

Authors:  Christian Plathow; Sebastian Ley; Christian Fink; Michael Puderbach; Melanie Heilmann; Ivan Zuna; Hans-Ulrich Kauczor
Journal:  Invest Radiol       Date:  2004-04       Impact factor: 6.016

4.  T1 mapping of the entire lung parenchyma: Influence of the respiratory phase in healthy individuals.

Authors:  Alfred Stadler; Peter M Jakob; Mark Griswold; Markus Barth; Alexander A Bankier
Journal:  J Magn Reson Imaging       Date:  2005-06       Impact factor: 4.813

5.  Magnetic resonance scanning in cystic fibrosis: comparison with computed tomography.

Authors:  D H Carr; P Oades; B Trotman-Dickenson; R Mohiaddin; A U Wells; A Bush
Journal:  Clin Radiol       Date:  1995-02       Impact factor: 2.350

6.  Cystic fibrosis: combined hyperpolarized 3He-enhanced and conventional proton MR imaging in the lung--preliminary observations.

Authors:  L F Donnelly; J R MacFall; H P McAdams; J M Majure; J Smith; D P Frush; P Bogonad; H C Charles; C E Ravin
Journal:  Radiology       Date:  1999-09       Impact factor: 11.105

7.  Contrast-enhanced 3D MRI of lung perfusion in children with cystic fibrosis--initial results.

Authors:  Monika Eichinger; Michael Puderbach; Christian Fink; Julie Gahr; Sebastian Ley; Christian Plathow; Siegfried Tuengerthal; Ivan Zuna; Frank-Michael Müller; Hans-Ulrich Kauczor
Journal:  Eur Radiol       Date:  2006-05-04       Impact factor: 5.315

8.  Quantitative analysis of regional airways obstruction using dynamic hyperpolarized 3He MRI-preliminary results in children with cystic fibrosis.

Authors:  Panos Koumellis; Edwin J R van Beek; Neil Woodhouse; Stan Fichele; Andrew J Swift; Martyn N J Paley; Catherine Hill; Chris J Taylor; Jim M Wild
Journal:  J Magn Reson Imaging       Date:  2005-09       Impact factor: 4.813

9.  Assessment of human pulmonary function using oxygen-enhanced T(1) imaging in patients with cystic fibrosis.

Authors:  Peter M Jakob; Tungte Wang; Georg Schultz; Helge Hebestreit; Alexandra Hebestreit; Dietbert Hahn
Journal:  Magn Reson Med       Date:  2004-05       Impact factor: 4.668

10.  Chronic thromboembolic pulmonary hypertension: pre- and postoperative assessment with breath-hold MR imaging techniques.

Authors:  Karl-Friedrich Jakob Kreitner; Sebastian Ley; Hans-Ulrich Kauczor; Eckhard Mayer; Thorsten Kramm; Michael Bernhard Pitton; Frank Krummenauer; Manfred Thelen
Journal:  Radiology       Date:  2004-06-23       Impact factor: 11.105

View more
  29 in total

1.  Evaluation and management of pulmonary disease in ataxia-telangiectasia.

Authors:  Sharon A McGrath-Morrow; W Adam Gower; Cynthia Rothblum-Oviatt; Alan S Brody; Claire Langston; Leland L Fan; Maureen A Lefton-Greif; Thomas O Crawford; Michelle Troche; John T Sandlund; Paul G Auwaerter; Blaine Easley; Gerald M Loughlin; John L Carroll; Howard M Lederman
Journal:  Pediatr Pulmonol       Date:  2010-09

2.  High resolution computed tomography of the chest in cystic fibrosis (CF): is simplification of scoring systems feasible?

Authors:  Anastasia Oikonomou; John Tsanakas; Elpis Hatziagorou; Fotios Kirvassilis; Stavros Efremidis; Panos Prassopoulos
Journal:  Eur Radiol       Date:  2007-11-27       Impact factor: 5.315

Review 3.  Can lung MR replace lung CT?

Authors:  Michael Puderbach; Hans-Ulrich Kauczor
Journal:  Pediatr Radiol       Date:  2008-06

Review 4.  Ten years of chest MRI for patients with cystic fibrosis : Translation from the bench to clinical routine.

Authors:  Patricia Leutz-Schmidt; Monika Eichinger; Mirjam Stahl; Olaf Sommerburg; Jürgen Biederer; Hans-Ulrich Kauczor; Michael U Puderbach; Marcus A Mall; Mark O Wielpütz
Journal:  Radiologe       Date:  2019-12       Impact factor: 0.635

Review 5.  The role of advanced imaging techniques in cystic fibrosis follow-up: is there a place for MRI?

Authors:  Michael Puderbach; Monika Eichinger
Journal:  Pediatr Radiol       Date:  2010-04-30

6.  New severity assessment in cystic fibrosis: signal intensity and lung volume compared to LCI and FEV1: preliminary results.

Authors:  Sabrina Fleischer; Mareen Sarah Kraus; Sergios Gatidis; Winfried Baden; Andreas Hector; Dominik Hartl; Ilias Tsiflikas; Juergen Frank Schaefer
Journal:  Eur Radiol       Date:  2019-11-14       Impact factor: 5.315

Review 7.  An official American Thoracic Society clinical practice guideline: classification, evaluation, and management of childhood interstitial lung disease in infancy.

Authors:  Geoffrey Kurland; Robin R Deterding; James S Hagood; Lisa R Young; Alan S Brody; Robert G Castile; Sharon Dell; Leland L Fan; Aaron Hamvas; Bettina C Hilman; Claire Langston; Lawrence M Nogee; Gregory J Redding
Journal:  Am J Respir Crit Care Med       Date:  2013-08-01       Impact factor: 21.405

8.  Chest MR imaging in the follow-up of pulmonary alterations in paediatric patients with middle lobe syndrome: comparison with chest X-ray.

Authors:  F Fraioli; G Serra; G Ciarlo; V Massaccesi; S Liberali; A Fiorelli; F Macrì; C Catalano
Journal:  Radiol Med       Date:  2012-10-22       Impact factor: 3.469

9.  Lung disease assessment in primary ciliary dyskinesia: a comparison between chest high-field magnetic resonance imaging and high-resolution computed tomography findings.

Authors:  Silvia Montella; Francesca Santamaria; Marco Salvatore; Marco Maglione; Paola Iacotucci; Maria Margherita De Santi; Carmine Mollica
Journal:  Ital J Pediatr       Date:  2009-08-06       Impact factor: 2.638

10.  Comparative evaluation of chest radiography, low-field MRI, the Shwachman-Kulczycki score and pulmonary function tests in patients with cystic fibrosis.

Authors:  Angela Anjorin; Helga Schmidt; Hans-Georg Posselt; Christina Smaczny; Hanns Ackermann; Michael Deimling; Thomas J Vogl; Nasreddin Abolmaali
Journal:  Eur Radiol       Date:  2008-02-15       Impact factor: 5.315

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.